BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...cancers from BioAtla LLC , and a mAb against PSMA to treat prostate cancer from BZL Biologics LLC...
...Cambridge, Mass. BioAtla LLC , San Diego, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. BZL Biologics LLC...
BioCentury | Jul 22, 2013
Company News

ADC Therapeutics, BZL Biologics deal

...Virgin Islands). The companies declined to disclose financial details. ADC Therapeutics S.a.r.l. , Lausanne, Switzerland BZL Biologics LLC...
BioCentury | Jun 18, 2012
Company News

BZL Biologics LLC, ImaginAb deal

...in development for prostate cancer diagnostics. Details were not disclosed (see BioCentury, Oct. 26, 2009). BZL Biologics LLC...
BioCentury | Oct 26, 2009
Company News

BZL Biologics LLC, ImaginAb deal

...in 2010. BZL is eligible for undisclosed milestones and royalties. Further terms were not disclosed. BZL Biologics LLC...
BioCentury | Nov 7, 2005
Strategy

Millennium pipeline

...MAb targeting prostate-specific membrane antigen plus DM1 chemotherapeutic Progressive metastatic hormone-refractory prostate cancer Ph I/II BZL Biologics...
BioCentury | Oct 22, 2001
Clinical News

J591 humanized monoclonal antibody: Phase I

...Molecular Medicine's New Trends in Prostate Cancer meeting in Padova, Italy. MLNM licensed J591 from BZL Biologics LLC...
BioCentury | Apr 16, 2001
Company News

BZL Biologics L.L.C., Millennium deal

...product. A radiolabeled form of J591 is in Phase I trials to treat prostate cancer. BZL Biologics...
BioCentury | Apr 11, 2001
Company News

Millennium antibody deal with BZL

...MLNM will use BZL Biologics' humanized J591 antibody to develop and commercialize both immunotoxin and radiolabeled antibodies...
BioCentury | Oct 30, 2000
Clinical News

huJ591 humanized antibody against PSMA regulatory update

...of the patent, is in Phase I testing with radiolabeled huJ591 to treat prostate cancer. BZL Biologics...
BioCentury | Aug 28, 2000
Clinical News

Monoclonal antibodies against PSMA regulatory update

...Phase I testing to treat prostate cancer, is the exclusive worldwide licensee of the patent. BZL Biologics...
Items per page:
1 - 10 of 15
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...cancers from BioAtla LLC , and a mAb against PSMA to treat prostate cancer from BZL Biologics LLC...
...Cambridge, Mass. BioAtla LLC , San Diego, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. BZL Biologics LLC...
BioCentury | Jul 22, 2013
Company News

ADC Therapeutics, BZL Biologics deal

...Virgin Islands). The companies declined to disclose financial details. ADC Therapeutics S.a.r.l. , Lausanne, Switzerland BZL Biologics LLC...
BioCentury | Jun 18, 2012
Company News

BZL Biologics LLC, ImaginAb deal

...in development for prostate cancer diagnostics. Details were not disclosed (see BioCentury, Oct. 26, 2009). BZL Biologics LLC...
BioCentury | Oct 26, 2009
Company News

BZL Biologics LLC, ImaginAb deal

...in 2010. BZL is eligible for undisclosed milestones and royalties. Further terms were not disclosed. BZL Biologics LLC...
BioCentury | Nov 7, 2005
Strategy

Millennium pipeline

...MAb targeting prostate-specific membrane antigen plus DM1 chemotherapeutic Progressive metastatic hormone-refractory prostate cancer Ph I/II BZL Biologics...
BioCentury | Oct 22, 2001
Clinical News

J591 humanized monoclonal antibody: Phase I

...Molecular Medicine's New Trends in Prostate Cancer meeting in Padova, Italy. MLNM licensed J591 from BZL Biologics LLC...
BioCentury | Apr 16, 2001
Company News

BZL Biologics L.L.C., Millennium deal

...product. A radiolabeled form of J591 is in Phase I trials to treat prostate cancer. BZL Biologics...
BioCentury | Apr 11, 2001
Company News

Millennium antibody deal with BZL

...MLNM will use BZL Biologics' humanized J591 antibody to develop and commercialize both immunotoxin and radiolabeled antibodies...
BioCentury | Oct 30, 2000
Clinical News

huJ591 humanized antibody against PSMA regulatory update

...of the patent, is in Phase I testing with radiolabeled huJ591 to treat prostate cancer. BZL Biologics...
BioCentury | Aug 28, 2000
Clinical News

Monoclonal antibodies against PSMA regulatory update

...Phase I testing to treat prostate cancer, is the exclusive worldwide licensee of the patent. BZL Biologics...
Items per page:
1 - 10 of 15